Moors & Cabot Inc. Has $2.04 Million Stake in Boston Scientific Co. (NYSE:BSX)

Moors & Cabot Inc. reduced its position in shares of Boston Scientific Co. (NYSE:BSX) by 0.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,543 shares of the medical equipment provider’s stock after selling 175 shares during the period. Moors & Cabot Inc.’s holdings in Boston Scientific were worth $2,044,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in BSX. Precision Wealth Strategies LLC bought a new position in Boston Scientific during the fourth quarter worth about $956,000. Aveo Capital Partners LLC increased its holdings in shares of Boston Scientific by 1.3% during the fourth quarter. Aveo Capital Partners LLC now owns 12,841 shares of the medical equipment provider’s stock worth $742,000 after purchasing an additional 171 shares during the period. Jump Financial LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $361,000. Independent Advisor Alliance bought a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $228,000. Finally, TrinityPoint Wealth LLC increased its stake in Boston Scientific by 5.9% during the 4th quarter. TrinityPoint Wealth LLC now owns 12,546 shares of the medical equipment provider’s stock worth $725,000 after acquiring an additional 697 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total transaction of $570,511.10. Following the completion of the sale, the executive vice president now directly owns 37,468 shares in the company, valued at approximately $3,061,135.60. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 20,949 shares of company stock worth $1,627,877 over the last quarter. Company insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. StockNews.com downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, September 13th. Argus boosted their target price on shares of Boston Scientific from $80.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, May 28th. Needham & Company LLC increased their price target on shares of Boston Scientific from $82.00 to $86.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. TD Cowen boosted their price objective on shares of Boston Scientific from $77.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $85.00 target price on shares of Boston Scientific in a report on Thursday, July 25th. Three research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.38.

Boston Scientific Trading Down 1.2 %

Shares of BSX stock opened at $82.52 on Wednesday. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $84.11. The company has a current ratio of 1.61, a quick ratio of 1.14 and a debt-to-equity ratio of 0.44. The stock has a market cap of $121.06 billion, a price-to-earnings ratio of 69.34, a PEG ratio of 2.75 and a beta of 0.79. The stock has a 50-day moving average of $78.35 and a 200-day moving average of $74.39.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The business had revenue of $4.12 billion during the quarter, compared to the consensus estimate of $4.02 billion. During the same quarter in the prior year, the firm posted $0.53 EPS. The company’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, equities research analysts forecast that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.